caa a22 4500 465738443 CHVBK 20180323111801.0 cr unu---uuuuu 170327e19900601xx s 000 0 eng 10.1007/BF02244122 doi (NATIONALLICENCE)springer-10.1007/BF02244122 Effects of morphine, ethylketocyclazocine, N -allylnormetazocine and naloxone on locomotor activity in the rabbit [Elektronische Daten] [C. Schindler, M. White, S. Goldberg] Locomotor activity was studied in the rabbit following injections of morphine, ethylketocyclazocine andN-allylnormetazocine. All three drugs produced only depression of activity. The opioid antagonist naloxone antagonized the effects of both morphine and ethylketocyclazocine. Naloxone (0.1 mg/kg) did not antagonize the effects ofN-allylnormetazocine. Naloxone alone depressed locomotor activity at doses above 0.3 mg/kg. This effect of naloxone was partially antagonized by 0.1 mg/kg ethylketocyclazocine, but not by 0.1 mg/kg morphine. The GABA agonist muscimol (0.1 and 1.0 mg/kg) also did not antagonize the effect of naloxone on locomotor activity. Finally, amphetamine did not produce a great deal of locomotor activation in the rabbit, which may indicate that increasing activity in the rabbit by drug intervention may be inherently difficult. These results indicate that the opioids have effects in the rabbit that are clearly different from those observed in rodents, where morphine andN-allylnormetazocine have been reported to produce locomotor activation, and naloxone typically has little effect. In addition, the effects of the opioids on locomotor activity were clearly distinguishable from their effects on learning in the rabbit. While morphine and ethylketocyclazocine were approximately equipotent in depressing locomotor activity, morphine is much less potent than ethylketocyclazocine in retarding acquisition of the classically conditioned nictitating membrane response in the rabbit. Springer-Verlag, 1990 Morphine nationallicence Ethylketocyclazocine nationallicence N -allylnormetazocine nationallicence Naloxone nationallicence Locomotor activity nationallicence Rabbit nationallicence Schindler C. NIDA Addiction Research Center, P.O. Box 5180, 21224, Baltimore, MD, USA aut White M. Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore, 21201, Baltimore, MD, USA aut Goldberg S. NIDA Addiction Research Center, P.O. Box 5180, 21224, Baltimore, MD, USA aut Psychopharmacology Springer-Verlag 101/2(1990-06-01), 172-177 0033-3158 101:2<172 1990 101 213 https://doi.org/10.1007/BF02244122 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244122 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schindler C. NIDA Addiction Research Center, P.O. Box 5180, 21224, Baltimore, MD, USA aut NATIONALLICENCE 700 1- White M. Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore, 21201, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Goldberg S. NIDA Addiction Research Center, P.O. Box 5180, 21224, Baltimore, MD, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/2(1990-06-01), 172-177 0033-3158 101:2<172 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer